Friday, September 19, 2014 Last update: 3:03 PM
FreshNews.com - All Company Technology News Since 1996

Ligand to Participate in Three Upcoming Investor Conferences

Companies mentioned in this article: Ligand Pharmaceuticals Incorporated

SAN DIEGO -- (BUSINESS WIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences:

  • Deutsche Bank 39th Annual Health Care Conference in Boston. Presentation on Wednesday, May 7, 2014 at 4:10 p.m. Eastern time (1:10 p.m. Pacific time).
  • Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas. Presentation on Tuesday, May 13, 2014 at 11:00 a.m. Eastern time (8:00 a.m. Pacific time).
  • Craig-Hallum 11th Annual Institutional Investor Conference in Minneapolis (no formal presentations). One-on-one and small-group meetings on Wednesday, May 28, 2014.

A live webcast of the presentations will be available on Ligand’s website at www.ligand.com. A replay of the presentations will be archived on the website for 30 days.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Lundbeck Inc., Eli Lilly & Co. and Spectrum Pharmaceuticals. Please visit www.captisol.com for more information on Captisol and www.ligand.com for more information on Ligand.

Follow Ligand on Twitter @Ligand_LGND.


Copyright © Business Wire 2014
Contact:

Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
(858) 550-7500
investors@ligand.com
@Ligand_LGND
or
LHA
Bruce Voss
(310) 691-7100
bvoss@lhai.com
@LHA_IR_PR